Evidence map›Paper›PMID 41593681›Full record

ArticleBiology of sex differences2026

Long-term sex differences in symptoms and immune profile in long COVID.

José Feliz, Juliana Gonçalves, Carolina Cabedo, José Brito, Maria Gamas, Maria Inês Neves, Helena Soares

Abstract read
In one paragraph

Article in Biology of sex differences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

José Feliz *Human Immunobiology and Pathogenesis Laboratory, iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, Portugal.
Juliana Gonçalves *Human Immunobiology and Pathogenesis Laboratory, iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, Portugal.
Carolina CabedoHuman Immunobiology and Pathogenesis Laboratory, iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, Portugal.
José BritoEgas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science, Caparica, Portugal.
Maria GamasHuman Immunobiology and Pathogenesis Laboratory, iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, Portugal.
Maria Inês NevesHuman Immunobiology and Pathogenesis Laboratory, iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, Portugal.
Helena SoaresHuman Immunobiology and Pathogenesis Laboratory, iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, Portugal. helena.soares@nms.unl.pt.

Funding

European Union's Horizon Europe research and innovation action through the projects MPS_NOVA Grant Agreement No. GA 101159729EVCA Grant Agreement No. GA 101079264Research Unit UID/04462: iNOVA4Health and by Associated Laboratory LS4FUTURE LA/P/0087/2020
6 · The paper itself

Abstract

backgroundLong COVID (LC) is a post-infectious condition affecting millions worldwide, characterized by persistent multisystem symptoms. Females are disproportionately affected, reporting higher symptom burden, particularly neurocognitive and neurosensory complaints. While short-term immunopathology has been described, the long-term clinical course, immune dysregulation, and sex-specific underpinnings remain poorly understood.

methodsWe analyzed 34 participants experiencing persisting symptoms from 9 months to 5 years post-SARS-CoV-2 infection, alongside 26 SARS-CoV-2-infected controls without symptoms. Clinical assessments, symptom inventories, comorbidity analysis, and work capacity evaluation were performed. Immune profiling included flow cytometry of CD4⁺ and CD8⁺ T cells, NK cells, and B cells, as well as quantification of plasma cytokines, soluble factors, and cytotoxic molecules, analyzed in a sex-disaggregated manner.

resultsFemales with LC exhibited higher symptom burden, particularly persistent fatigue, neurocognitive and neurosensory complaints, which increased with age and tended to increase with disease duration, whereas males showed no clear age- or duration-related patterns. Comorbidities, especially affecting endocrine, metabolic, and circulatory systems, were more frequent in females and aligned with symptom severity. Immune profiling revealed subtle but sex-specific differences: females had reduced CD8⁺ T cell cytotoxic profile, lower NKG2D and granzyme K expression, increased sCD40L and sFAS, and decreased perforin, whereas males displayed elevated TNF-α. NK cell function, B cells, and humoral immunity remained largely intact. Over half of participants reported functional impairments affecting work capacity.

conclusionsEven though our cohort is small it suggests that prolonged LC is characterized by sex-specific differences in symptom burden and immune profiles. Reduced cytotoxic CD8⁺ T cell profile in females may contribute to viral persistence and neurological symptoms, whereas elevated inflammatory markers in males suggest distinct immune pathways. These findings highlight the need for sex- and duration-specific management strategies, the identification of biomarkers, and the development of personalized therapies targeting specific LC endotypes.

Indexed as

COVID-19Sex CharacteristicsAdultAgedCytokinesFemaleHumansKiller Cells, NaturalMaleMiddle AgedPost-Acute COVID-19 SyndromeSARS-CoV-2Symptom BurdenCytokinesCellular and molecular signaturesImmune dysregulationLong COVIDLong-term symptom persistenceSex differential immunity

Identifiers

PMID41593681
PMCPMC12918094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.